Literature DB >> 18508533

Does MK5 reconcile classical and atypical MAP kinases?

Maria Perander1, Stephen M Keyse, Ole-Morten Seternes.   

Abstract

MAP kinase-activated protein kinase 5 (MK5) was originally described as a protein kinase activated downstream of the p38 MAP kinase and is also named p38-regulated/activated protein kinase (PRAK). However, while MK5 is most similar in sequence to the two p38 regulated MAPKAP kinases MK2 and MK3, recent data has shown that in contrast to these enzymes MK5 is not activated in response to either cellular stress or pro-inflammatory cytokines. This lack of response to stimuli which cause robust activation of p38 MAP kinase in vivo is supported by data obtained using transgenic mice lacking MK5. Unlike animals lacking MK2 and MK3, MK5 null mice respond normally to endotoxic shock and display an unchanged pattern of cytokine expression in response to LPS. Clues as to the physiological function of MK5 have come from the recent observation that MK5 is uniquely regulated and activated following complex formation with the atypical MAP kinases ERK3 and ERK4. Thus, it is possible that MK5 is unique amongst the MAPKAP kinases in being regulated downstream of signaling pathways other than the classical MAP kinases p38 and ERK1/2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508533     DOI: 10.2741/3027

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  12 in total

1.  The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor.

Authors:  Sergiy Kostenko; Mahmud Tareq Hassan Khan; Ingebrigt Sylte; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2010-07-17       Impact factor: 9.261

Review 2.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

3.  Absence of a human DnaJ protein hTid-1S correlates with aberrant actin cytoskeleton organization in lesional psoriatic skin.

Authors:  Ji Hye Choi; Dae-Kyoung Choi; Kyung-Cheol Sohn; Sang Su Kwak; Jinkyu Suk; Jong-Soon Lim; Incheol Shin; Sung-Woo Kim; Jeung-Hoon Lee; Cheol O Joe
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

Review 4.  The discovery of novel experimental therapies for inflammatory arthritis.

Authors:  Charles J Malemud
Journal:  Mediators Inflamm       Date:  2010-03-18       Impact factor: 4.711

5.  The catalytic activity of the mitogen-activated protein kinase extracellular signal-regulated kinase 3 is required to sustain CD4+ CD8+ thymocyte survival.

Authors:  Miriam Marquis; Jean-François Daudelin; Salix Boulet; Julien Sirois; Karinn Crain; Simon Mathien; Benjamin Turgeon; Justine Rousseau; Sylvain Meloche; Nathalie Labrecque
Journal:  Mol Cell Biol       Date:  2014-07-07       Impact factor: 4.272

6.  Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5.

Authors:  Sergiy Kostenko; Gianina Dumitriu; Ugo Moens
Journal:  J Mol Signal       Date:  2012-07-16

7.  Serine residue 115 of MAPK-activated protein kinase MK5 is crucial for its PKA-regulated nuclear export and biological function.

Authors:  Sergiy Kostenko; Alexey Shiryaev; Nancy Gerits; Gianina Dumitriu; Helle Klenow; Mona Johannessen; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2010-08-25       Impact factor: 9.261

8.  Distinct roles of MK2 and MK5 in cAMP/PKA- and stress/p38MAPK-induced heat shock protein 27 phosphorylation.

Authors:  Alexey Shiryaev; Gianina Dumitriu; Ugo Moens
Journal:  J Mol Signal       Date:  2011-05-16

9.  TLK1-mediated MK5-S354 phosphorylation drives prostate cancer cell motility and may signify distinct pathologies.

Authors:  Md Imtiaz Khalil; Vibha Singh; Judy King; Arrigo De Benedetti
Journal:  Mol Oncol       Date:  2022-02-03       Impact factor: 7.449

10.  Homology modeling and ligand docking of Mitogen-activated protein kinase-activated protein kinase 5 (MK5).

Authors:  Inger Lindin; Yimingjiang Wuxiuer; Irina Kufareva; Ruben Abagyan; Ugo Moens; Ingebrigt Sylte; Aina Westrheim Ravna
Journal:  Theor Biol Med Model       Date:  2013-09-14       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.